Hämatologie 2008

Was ist neu?

• Antikoagulation: Thromboseprophylaxe mit Rivaroxaban (M. Hellmann, M. Kochanek)

• Eculizimab: Komplement-Inhibition als Therapie der paroxysmalen nächtlichen Hämoglobinurie (P. Borchmann)

• Chronische lymphatische Leukämie: Therapiestrategie in Abhängigkeit von der Fitness des Patienten (B. Eichhorst, M. Hallek)

• Multiples Myelom: Immunmodulation mit Lenalidomid (K. Hübel)

• Myelodysplastisches Syndrom: Epigenetische Therapien (K. Kreuzer)

• Indolente Lymphome: Ibritumomab-Tiuxetan/Bendamustin + Rituximab (M. Reiser)

• Hodgkin Lymphom: Die Positronen-Emissions-Tomographie als Methode zur Therapieentscheidung (P. Borchmann)

• Akute myeloische Leukämie: Molekulare Risikostratifizierung (K. Kreuzer)

Literatur

• 1 Agnelli G, Gallus A, Goldhaber S Z, Haas S, Huisman M V, Hull R D, Kakkar A K, Misselwitz F, Schellong S. et al, ODIXa-DVT Study Investigators . Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59 - 7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59 - 7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study.  Circulation. 2007;  116 180-187
• 2 Boultwood J, Wainscoat J S. Gene silencing by DNA methylation in haematological malignancies.  Br J Haematol. 2007;  138 3-11
• 3 Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukaemia from the 1980 s to the early 21st century.  Blood. 2008; 
• 4 Büller H R, Agnelli G. the EINSTEIN-DVT and ODIXa-DVT Study groups . Once or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficiacy and safety to standard therapy in dose-ranging studies.  Blood. 2006;  108
• 5 Catovsky D, Richards S, Matutes E. et al . Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.  Lancet. 2007;  370 230-239
• 6 Diehl V, Kobe C, Haverkamp H. et al . FDG-PET for Assessment of Residual Tissue after Completion of Chemotherapy in Hodgkin Lymphoma - Report on the 2nd Interim Analysis of the PET Investigation in the Trial HD15 of the GHSG.  Blood (ASH Annual Meeting Abstracts). Nov 2007;  110 212
• 7 Dimopoulos M, Spencer A, Attal M. et al . Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.  N Engl J Med. 2007;  357 2123-2132
• 8 Eichhorst B F, Busch R, Stauch M. et al . No significant clinical benefit of fist line therapy with fludarabine (F) in comparison to chlorambucil (Clb) in elderly patients (pts) with advanced chronic lymphocytic leukaemia (CLL): results of a phase III study of the German CLL study group (GCLLSG).  Blood. 2007;  110
• 9 Grövdal M, Khan R, Aggerholm A. et al . Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome.  Clin Cancer Res. 2007;  13 7107-7112
• 10 Hagenbeek. et al . 90Y-Ibritumomab Tiuxetan (Zevalin) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkins Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients.  Blood. 2007;  110
• 11 Hagenbeek A, Bischof-Delaloye A, Radford J A. et al . 90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients.  Blood (ASH Annual Meeting Abstracts). Nov 2007;  110 643
• 12 Hillmen P, Muus P, Duhrsen U. et al . Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.  Blood. 2007;  110 4123-4128
• 13 Hillmen P, Skotnicki A B, Robak T. et al . Alemtuzamab compared with chlorambucil as first-line therapy for chronic lymphocytic leukaemia.  J Clin Oncol. 2007; 
• 14 Hillmen P, Young N S, Schubert J. et al . The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.  N Engl J Med. 2006;  355 1233-1243
• 15 Kantarjian H, Issa J P, Rosenfeld C S. et al . Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.  Cancer. 2006;  106 1794-1803
• 16 Kantarjian H M, O’Brien S, Shan J. et al . Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.  Cancer. 2007;  109 265-273
• 17 Kantarjian H M, Oki Y, Garcia-Manero G. et al . Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.  Blood. 2007;  109 52-57
• 18 Knauf W, Lissichkov T. et al . Bendamustine versus Chlorambucin in treatment-naïve patients with B-cell chronic lymphocytic leukaemia (B-CLL): results of an international phase III study.  Blood. 2007;  110
• 19 Lassen M R, Turpie A G, Rosencher N, Borris L C. et al . Rivaroxaban - an oral direct Factor Xa inhibitor - for thromboprophylaxis after total knee arthroplasty: the RECORD3 trial.  Blood. 2007;  110
• 20 Lyons R, Cosgriff T, Modi S. et al . Azacytidine (Vidaza) treatment response assessed using three alternative dosing schedules in pat9ients with myelodysplastic syndromes.  Blood. 2005;  106 707a
• 21 Oliansky D M, Appelbaum F, Cassileth P A. et al . The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review.  Biol Blood Marrow Transplant. 2008;  14 137-180
• 22 Rajkumar S V, Jacobus S, Callander N. et al . A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group.  Blood. 2007;  110 74
• 23 Rosse W F. et al . Immune-mediated hemolytic anemia.  Hematology Am Soc Hematol Educ Program. 2004;  48-62
• 24 Rossetti J, Falke E, Shadduck. et al . G-CSF increases hematological responses among patients with myelodysplasia treated with azacitidine.  Blood. 2006;  108 303b
• 25 Rummel. et al . Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).  Blood. 2007;  110
• 26 Schnittger S, Schoch C, Dugas M. et al . Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.  Blood. 2002;  100 59-66
• 27 Schulz. et al . Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.  J Natl Cancer Inst. 2007;  99 706-714
• 28 Silverman L R, McKenzie D R, Peterson B L. et al . Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.  J Clin Oncol. 2006;  24 3895-3903
• 29 Weber D M, Chen C, Niesvizky R. et al . Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.  N Engl J Med. 2007;  357 2133-2142
• 30 Zhang W, Konopleva M, Shi Y X. et al . Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.  J Natl Cancer Inst. 2008;  100 184-198